{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:54:49Z","timestamp":1740135289261,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Science Foundation of China","doi-asserted-by":"crossref","award":["81770698"],"award-info":[{"award-number":["81770698"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100018617","name":"liao ning revitalization talents program","doi-asserted-by":"crossref","award":["XLYC2002081"],"award-info":[{"award-number":["XLYC2002081"]}],"id":[{"id":"10.13039\/501100018617","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Key R&D Program of China","award":["2017YFC0907400"],"award-info":[{"award-number":["2017YFC0907400"]}]},{"name":"Key R & D guidance plan of Liaoning Province","award":["2019JH8\/10300009"],"award-info":[{"award-number":["2019JH8\/10300009"]}]},{"name":"Pandeng Scholar of Education Department of Liaoning Province","award":["2013222"],"award-info":[{"award-number":["2013222"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Cases of concurrent immunoglobulin A nephropathy (IgAN) and IgG4-related tubulointerstitial nephritis (IgG4-TIN) are rare and previous case reports have lacked important data. KDIGO suggests a treatment with systemic glucocorticoids in IgAN patients. Glucocorticoids are recommended as the first-line therapy for IgG4-TIN. The use of tacrolimus as a long-term maintenance treatment has not been described. We report the case of a man who developed IgAN and IgG4-TIN without abnormalities in extra-renal tissue, without renal function abnormalities or impairment as well, and was treated by tacrolimus as a long-term maintenance during 45\u2009months follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 56-year-old Chinese man first presented to our hospital with the chief complaint of foamy urine for 1 year and hematuria for 3 months, with a medical history of hypertension. Testing revealed a notable increase in serum IgG4 level without abnormalities in renal function or imaging, or in dysfunction other organs. Renal biopsy showed mesangial extracellular matrix\u00a0proliferation, increased mesangial cell numbers and infiltration of plasma cells. Immunofluorescence showed mesangial positivity for IgA and C3. Immunohistochemistry staining showed widespread IgG4 and increased CD38 and CD138 expression. Electron microscopy showed immune complexes located on the tubular basement membrane. He was diagnosed with IgAN and IgG4-TIN. He received glucocorticoids, leflunomide and tacrolimus to induce remission. He was given tacrolimus as long-term maintenance treatment. When tacrolimus was temporarily withdrawn, proteinuria recurred. After resuming tacrolimus therapy, he again entered complete remission. After 45\u2009months of therapy, he remains in complete remission and the serum IgG4 level is normal.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The finding of concurrent IgAN and IgG4-TIN without abnormalities in renal function, imaging or extra-renal tissue is rare and their coexistence may be coincidental. Long-term treatment with tacrolimus proved effective and he has remained in remission during 45\u2009months follow-up.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12882-021-02477-w","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T10:03:43Z","timestamp":1628762623000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Co-occurrence of IgA nephropathy and IgG4-Tubulointersitial nephritis effectively treated with tacrolimus: a case report"],"prefix":"10.1186","volume":"22","author":[{"given":"Mi","family":"Tian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjun","family":"Luan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Congcong","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey B.","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0429-116X","authenticated-orcid":false,"given":"Hua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,12]]},"reference":[{"issue":"5","key":"2477_CR1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.semnephrol.2018.05.013","volume":"38","author":"F Schena","year":"2018","unstructured":"Schena F, Nistor I. Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol. 2018;38(5):435\u201342.","journal-title":"Semin Nephrol"},{"issue":"11","key":"2477_CR2","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/ng.3118","volume":"46","author":"K Kiryluk","year":"2014","unstructured":"Kiryluk K, Li Y, Scolari F, Sanna-Cherchi S, Choi M, Verbitsky M, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet. 2014;46(11):1187\u201396.","journal-title":"Nat Genet"},{"issue":"5","key":"2477_CR3","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/ki.2009.168","volume":"76","author":"I Roberts","year":"2009","unstructured":"Roberts I, Cook H, Troyanov S, Alpers C, Amore A, Barratt J, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009;76(5):546\u201356.","journal-title":"Kidney Int"},{"issue":"12","key":"2477_CR4","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1681\/ASN.2016010093","volume":"27","author":"X Xu","year":"2016","unstructured":"Xu X, Wang G, Chen N, Lu T, Nie S, Xu G, et al. Long-term exposure to air pollution and increased risk of membranous nephropathy in China. J Am Soc Nephrol. 2016;27(12):3739\u201346.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"2477_CR5","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1038\/ki.2010.271","volume":"78","author":"T Saeki","year":"2010","unstructured":"Saeki T, Nishi S, Imai N, Ito T, Yamazaki H, Kawano M, et al. Clinicopathological characteristics of patients with IgG4-related tubulointerstitial nephritis. Kidney Int. 2010;78(10):1016\u201323.","journal-title":"Kidney Int"},{"issue":"7","key":"2477_CR6","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1681\/ASN.2011010062","volume":"22","author":"Y Raissian","year":"2011","unstructured":"Raissian Y, Nasr S, Larsen C, Colvin R, Smyrk T, Takahashi N, et al. Diagnosis of IgG4-related tubulointerstitial nephritis. J Am Soc Nephrol. 2011;22(7):1343\u201352.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"2477_CR7","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1093\/rheumatology\/kev203","volume":"54","author":"W Lin","year":"2015","unstructured":"Lin W, Lu S, Chen H, Wu Q, Fei Y, Li M, et al. Clinical characteristics of immunoglobulin G4-related disease: a prospective study of 118 Chinese patients. Rheumatology (Oxford). 2015;54(11):1982\u201390.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"2477_CR8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1053\/j.semdp.2012.07.004","volume":"29","author":"L Cornell","year":"2012","unstructured":"Cornell L. IgG4-related kidney disease. Semin Diagn Pathol. 2012;29(4):245\u201350.","journal-title":"Semin Diagn Pathol"},{"issue":"2","key":"2477_CR9","first-page":"279","volume":"37","author":"G Wang","year":"2019","unstructured":"Wang G, Chen Y, Cheng H, Xu X, Sun L, Dong H. Antineutrophil cytoplasmic antibody and\/or antiglomerular basement membrane antibody associated crescentic glomerulonephritis in combination with IgG4-related tubulointerstitial nephritis. Clin Exp Rheumatol. 2019;37(2):279\u201385.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"2477_CR10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/MNH.0000000000000102","volume":"24","author":"M Kawano","year":"2015","unstructured":"Kawano M, Saeki T. IgG4-related kidney disease--an update. Curr Opin Nephrol Hypertens. 2015;24(2):193\u2013201.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"11","key":"2477_CR11","doi-asserted-by":"publisher","first-page":"e0188375","DOI":"10.1371\/journal.pone.0188375","volume":"12","author":"M Yu","year":"2017","unstructured":"Yu M, Kim Y, Koo H, Chin H. Short-term anti-proteinuric effect of tacrolimus is not related to preservation of the glomerular filtration rate in IgA nephropathy: a 5-year follow-up study. PLoS One. 2017;12(11):e0188375.","journal-title":"PLoS One"},{"issue":"1","key":"2477_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1136\/annrheumdis-2019-216561","volume":"79","author":"Z Wallace","year":"2020","unstructured":"Wallace Z, Naden R, Chari S, Choi H, Della-Torre E, Dicaire J, et al. The 2019 American College of Rheumatology\/European league against rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis. 2020;79(1):77\u201387.","journal-title":"Ann Rheum Dis"},{"key":"2477_CR13","doi-asserted-by":"crossref","unstructured":"Floege J, Barbour SJ, Cattran DC, Hogan JJ, Nachman PH, Tang SCW, et al. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019;95(2):268-280.","DOI":"10.1016\/j.kint.2018.10.018"},{"key":"2477_CR14","doi-asserted-by":"crossref","unstructured":"Tan J, Dong L, Ye D, Tang Y, Hu T, Zhong Z, et al. The efficacy and safety of immunosuppressive therapies in the treatment of IgA nephropathy: A network meta-analysis. Sci Rep. 2020;10(1):6062.","DOI":"10.1038\/s41598-020-63170-w"},{"issue":"3","key":"2477_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1053\/j.semdp.2020.03.001","volume":"37","author":"J Hassler","year":"2020","unstructured":"Hassler J. IgA nephropathy: a brief review. Semin Diagn Pathol. 2020;37(3):143\u20137.","journal-title":"Semin Diagn Pathol"},{"issue":"6","key":"2477_CR16","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMra1104650","volume":"366","author":"J Stone","year":"2012","unstructured":"Stone J, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012;366(6):539\u201351.","journal-title":"N Engl J Med"},{"issue":"9976","key":"2477_CR17","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(14)60720-0","volume":"385","author":"T Kamisawa","year":"2015","unstructured":"Kamisawa T, Zen Y, Pillai S, Stone J. IgG4-related disease. Lancet. 2015;385(9976):1460\u201371.","journal-title":"Lancet."},{"issue":"5","key":"2477_CR18","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10157-011-0521-2","volume":"15","author":"M Kawano","year":"2011","unstructured":"Kawano M, Saeki T, Nakashima H, Nishi S, Yamaguchi Y, Hisano S, et al. Proposal for diagnostic criteria for IgG4-related kidney disease. Clin Exp Nephrol. 2011;15(5):615\u201326.","journal-title":"Clin Exp Nephrol"},{"issue":"10","key":"2477_CR19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nrneph.2015.95","volume":"11","author":"F Cortazar","year":"2015","unstructured":"Cortazar F, Stone J. IgG4-related disease and the kidney. Nat Rev Nephrol. 2015;11(10):599\u2013609.","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"2477_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1053\/j.ackd.2016.12.001","volume":"24","author":"P Zhang","year":"2017","unstructured":"Zhang P, Cornell L. IgG4-related Tubulointerstitial nephritis. Adv Chronic Kidney Dis. 2017;24(2):94\u2013100.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"25","key":"2477_CR21","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1056\/NEJMra1206793","volume":"368","author":"R Wyatt","year":"2013","unstructured":"Wyatt R, Julian B. IgA nephropathy. N Engl J Med. 2013;368(25):2402\u201314.","journal-title":"N Engl J Med"},{"issue":"2","key":"2477_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/ki.2013.393","volume":"85","author":"T Saeki","year":"2014","unstructured":"Saeki T, Kawano M. IgG4-related kidney disease. Kidney Int. 2014;85(2):251\u20137.","journal-title":"Kidney Int"},{"issue":"1","key":"2477_CR23","doi-asserted-by":"publisher","first-page":"6195","DOI":"10.1038\/s41598-017-06520-5","volume":"7","author":"F Yunyun","year":"2017","unstructured":"Yunyun F, Yu C, Panpan Z, Hua C, Di W, Lidan Z, et al. Efficacy of cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids. Sci Rep. 2017;7(1):6195.","journal-title":"Sci Rep"},{"issue":"11","key":"2477_CR24","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1248\/bpb.b17-00134","volume":"40","author":"Z Wang","year":"2017","unstructured":"Wang Z, Yu C, Zhou L, Chen X. Effects of Tripterygium wilfordii induction therapy to IgA nephropathy patients with heavy proteinuria. Biol Pharm Bull. 2017;40(11):1833\u20138.","journal-title":"Biol Pharm Bull"},{"issue":"4","key":"2477_CR25","doi-asserted-by":"crossref","first-page":"437","DOI":"10.4103\/njcp.njcp_112_18","volume":"23","author":"J Zheng","year":"2020","unstructured":"Zheng J, Gong X, Wu Z. Immunosuppressive agents in the treatment of IgA nephropathy: a meta-analysis of clinical randomized controlled literature. Niger J Clin Pract. 2020;23(4):437\u201349.","journal-title":"Niger J Clin Pract"},{"issue":"8","key":"2477_CR26","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1177\/0300060518776566","volume":"46","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Luo J, Hu B, Ma T. Efficacy and safety of tacrolimus combined with glucocorticoid treatment for IgA nephropathy: a meta-analysis. J Int Med Res. 2018;46(8):3236\u201350.","journal-title":"J Int Med Res"},{"issue":"35","key":"2477_CR27","doi-asserted-by":"publisher","first-page":"e4731","DOI":"10.1097\/MD.0000000000004731","volume":"95","author":"W Peng","year":"2016","unstructured":"Peng W, Tang Y, Jiang Z, Li Z, Mi X, Qin W. The effect of calcineurin inhibitors in the treatment of IgA nephropathy: a systematic review and meta-analysis (PRISMA). Medicine. 2016;95(35):e4731.","journal-title":"Medicine."},{"issue":"1","key":"2477_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12882-017-0467-z","volume":"18","author":"Y Song","year":"2017","unstructured":"Song Y, Cai G, Xiao Y, Wang Y, Yuan B, Xia Y, et al. Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis. BMC Nephrol. 2017;18(1):61.","journal-title":"BMC Nephrol"},{"issue":"2","key":"2477_CR29","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s11255-012-0205-1","volume":"45","author":"L Fan","year":"2013","unstructured":"Fan L, Liu Q, Liao Y, Li Z, Ji Y, Yang Z, et al. Tacrolimus is an alternative therapy option for the treatment of adult steroid-resistant nephrotic syndrome: a prospective, multicenter clinical trial. Int Urol Nephrol. 2013;45(2):459\u201368.","journal-title":"Int Urol Nephrol"},{"issue":"5","key":"2477_CR30","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1080\/14397595.2018.1532560","volume":"29","author":"S Takanashi","year":"2019","unstructured":"Takanashi S, Kaneko Y, Takeuchi T. Effectiveness of tacrolimus on IgG4-related disease. Mod Rheumatol. 2019;29(5):892\u20134.","journal-title":"Mod Rheumatol"},{"issue":"2","key":"2477_CR31","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1093\/rheumatology\/kex171","volume":"57","author":"M Akiyama","year":"2018","unstructured":"Akiyama M, Suzuki K, Yasuoka H, Kaneko Y, Yamaoka K, Takeuchi T. Follicular helper T cells in the pathogenesis of IgG4-related disease. Rheumatology (Oxford). 2018;57(2):236\u201345.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"2477_CR32","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1002\/art.39209","volume":"67","author":"M Akiyama","year":"2015","unstructured":"Akiyama M, Suzuki K, Yamaoka K, Yasuoka H, Takeshita M, Kaneko Y, et al. Number of circulating follicular helper 2 T cells correlates with IgG4 and Interleukin-4 levels and Plasmablast numbers in IgG4-related disease. Arthritis Rheumatol. 2015;67(9):2476\u201381.","journal-title":"Arthritis Rheumatol"},{"key":"2477_CR33","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13075-016-1064-4","volume":"18","author":"M Akiyama","year":"2016","unstructured":"Akiyama M, Yasuoka H, Yamaoka K, Suzuki K, Kaneko Y, Kondo H, et al. Enhanced IgG4 production by follicular helper 2 T cells and the involvement of follicular helper 1 T cells in the pathogenesis of IgG4-related disease. Arthritis Res Ther. 2016;18:167.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"2477_CR34","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.jbspin.2018.01.014","volume":"85","author":"A Fern\u00e1ndez-Codina","year":"2018","unstructured":"Fern\u00e1ndez-Codina A, Pinilla B, Pinal-Fern\u00e1ndez I, L\u00f3pez C, Fraile-Rodr\u00edguez G, Fonseca-Aizpuru E, et al. Treatment and outcomes in patients with IgG4-related disease using the IgG4 responder index. Joint Bone Spine. 2018;85(6):721\u20136.","journal-title":"Joint Bone Spine"},{"key":"2477_CR35","doi-asserted-by":"publisher","first-page":"259408","DOI":"10.1155\/2012\/259408","volume":"2012","author":"M Carruthers","year":"2012","unstructured":"Carruthers M, Stone J, Deshpande V, Khosroshahi A. Development of an IgG4-RD responder index. Int J Rheumatol. 2012;2012:259408.","journal-title":"Int J Rheumatol"},{"issue":"11","key":"2477_CR36","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1002\/acr.23543","volume":"70","author":"Z Wallace","year":"2018","unstructured":"Wallace Z, Khosroshahi A, Carruthers M, Perugino C, Choi H, Campochiaro C, et al. An international multispecialty validation study of the IgG4-related disease responder index. Arthritis Care Res (Hoboken). 2018;70(11):1671\u20138.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2477_CR37","doi-asserted-by":"crossref","unstructured":"Yi J, He Z, Xu S, Feng S. Efficacy and safety of leflunomide in IgA nephropathy: a systematic review and meta-analysis. Int Urol Nephrol. 2019;51(11):1987-1998.","DOI":"10.1007\/s11255-019-02255-6"},{"issue":"6","key":"2477_CR38","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/imj.13430","volume":"47","author":"Y Wang","year":"2017","unstructured":"Wang Y, Li K, Gao D, Luo G, Zhao Y, Wang X, et al. Combination therapy of leflunomide and glucocorticoids for the maintenance of remission in patients with IgG4-related disease: a retrospective study and literature review. Intern Med J. 2017;47(6):680\u20139.","journal-title":"Intern Med J"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02477-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-021-02477-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02477-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T08:12:06Z","timestamp":1699344726000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-021-02477-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,12]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2477"],"URL":"https:\/\/doi.org\/10.1186\/s12882-021-02477-w","relation":{},"ISSN":["1471-2369"],"issn-type":[{"type":"electronic","value":"1471-2369"}],"subject":[],"published":{"date-parts":[[2021,8,12]]},"assertion":[{"value":"24 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A human subject research protocol was approved in advance by the Institutional Review Boards of Affiliated Hospital of China Medical University. The patient provided written informed consent prior to research participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"279"}}